ATTR-CM (transthyretin amyloid cardiomyopathy) is an often misdiagnosed, rare cause of heart failure. Because its symptoms can be subtle and similar to other, more common diseases, ATTR-CM can be difficult to recognize before it becomes advanced. Consistently identifying ATTR-CM patients in early stages of cardiomyopathy could increase the number and quality of years they live after diagnosis.

There’s no silver bullet strategy that will solve the multiple challenges that ATTR-CM presents, so the sample strategies highlighted below can be mixed and matched according to your health system’s needs and capacity. Ideally, health systems will combine multiple strategies to build a comprehensive solution.

Read on for the six strategies you should consider implementing to improve your system’s detection of ATTR-CM.

At Pfizer we’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place.

Our unique resources allow us to do more for people. Using our global presence and scale, we’re able to make a difference in local communities and the world around us.

Pfizer supports the global healthcare community’s independent quality improvement initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. For more information, please visit www.pfizer.com.

This infographic is sponsored by Pfizer, an Advisory Board member organization. Representatives of Pfizer helped select the topics and issues addressed. Advisory Board experts maintained final editorial approval, and conducted the underlying research independently and objectively. Advisory Board does not endorse any company, organization, product or brand mentioned herein.

View Advisory Board's editorial guidelines